

DRUG METABOLISM AND DISPOSITION

A Publication of the American Society for Pharmacology and Experimental Therapeutics

December 2006

Vol. 34, No. 12

CONTENTS

SHORT COMMUNICATIONS

Influence of Hydroxyurea On Imatinib Mesylate (Gleevec) Transport at the Mouse Blood-Brain Barrier. SÉBASTIEN BIHOREL, GIAN CAMENISCH, GERHARD GROSS, MICHEL LEMAIRE, AND JEAN-MICHEL SCHERRMANN **1945**

Sulfinpyrazone C-Glucuronidation Is Catalyzed Selectively by Human UDP-Glucuronosyltransferase 1A9. ORANUN KERDPIN, DAVID J. ELLIOT, PETER I. MACKENZIE, AND JOHN O. MINERS **1950**

Identification of Binding Sites of Non-I-Helix Water Molecules in Mammalian Cytochromes P450. CHARLES W. LOCUSON AND TIMOTHY S. TRACY . . . **1954**

ARTICLES

Engineering of Cytochrome P450 3A4 for Enhanced Peroxide-Mediated Substrate Oxidation Using Directed Evolution and Site-Directed Mutagenesis. SANTOSH KUMAR, HONG LIU, AND JAMES R. HALPERT **1958**

CYP2C9 Inhibition: Impact of Probe Selection and Pharmacogenetics on in Vitro Inhibition Profiles. VIKAS KUMAR, JAN L. WAHLSTROM, DAN A. ROCK, CHAD J. WARREN, LEE A. GORMAN, AND TIMOTHY S. TRACY **1966**

Rapid Identification of P-glycoprotein Substrates and Inhibitors. CHENG CHANG, PRAVEEN M. BAHADURI, JAMES E. POLLI, PETER W. SWAAN, AND SEAN EKINS **1976**

CYP4F Enzymes Are the Major Enzymes in Human Liver Microsomes That Catalyze the O-Demethylation of the Antiparasitic Prodrug DB289 [2,5-Bis(4-amidinophenyl)furan-bis-O-methylami-

doxime]. MICHAEL ZHUO WANG, JANELLE Y. SAULTER, ETSUKO USUKI, YEN-LING CHEUNG, MICHAEL HALL, ARLENE S. BRIDGES, GREG LOEWEN, OLIVER T. PARKINSON, CHAD E. STEPHENS, JAMES L. ALLEN, DARRYL C. ZELDIN, DAVID W. BOYKIN, RICHARD R. TIDWELL, ANDREW PARKINSON, MARY F. PAINE, AND JAMES EDWIN HALL **1985**

Investigation of Structure and Function of a Catalytically Efficient Variant of the Human Flavin-Containing Monooxygenase Form 3. TÍMEA BORBÁS, JUN ZHANG, MATT A. CERNY, ISTVÁN LIKÓ, AND JOHN R. CASHMAN **1995**

Phenytoin Induction of the *Cyp2c37* Gene Is Mediated by the Constitutive Androstane Receptor. JONATHAN P. JACKSON, STEPHEN S. FERGUSON, MASAHIKO NEGISHI, AND JOYCE A. GOLDSTEIN **2003**

Characterization of Human Urinary Metabolites of the Antimalarial Piperaquine. J. TARNING, Y. BERGQVIST, N. P. DAY, J. BERGQUIST, B. ARVIDSSON, N. J. WHITE, M. ASHTON, AND N. LINDEGÅRDH . . . **2011**

Comparative Metabolism and Disposition of Trichloroethylene in *Cyp2e1*^{-/-} and Wild-Type Mice. DOJUNG KIM AND BURHAN I. GHANAYEM **2020**

Pharmacokinetics and Metabolism in Mice of IDN 5390 (13-(*N*-Boc-3-*i*-butylisoserinoyl)-*C*-7,8-*seco*-10-deacetylbaicatin III), a New Oral *C*-*seco*-Taxane Derivative with Antiangiogenic Property Effective on Paclitaxel-Resistant Tumors. R. FRAPOLLI, E. MARANGON, M. ZAFFARONI, T. COLOMBO, C. FALCIONI, R. BAGNATI, M. SIMONE, M. D'INCALCI, C. MANZOTTI, G. FONTANA, P. MORAZZONI, AND M. ZUCCHETTI **2028**

In Vivo Metabolism of L-Methionine in Mice: Evidence for Stereoselective Formation of

Continued on next page

Methionine- <i>d</i> -Sulfoxide and Quantitation of Other Major Metabolites. JOSEPH T. DEVER AND ADNAN A. ELFARRA	2036	ANNE S. KIENHUIS, HELEEN M. WORTELBOER, JEAN-CHRISTOPHE HOFACK, EDWIN J. MOONEN, JOS C.S. KLEINJANS, BEN VAN OMMEN, JOOST H. M. VAN DELFT, AND ROB H. STIERUM	2083
Metabolic Aromatization of <i>N</i> -Alkyl-1,2,3,4-Tetrahydroquinoline Substructures to Quinolinium by Human Liver Microsomes and Horseradish Peroxidase. CHUNGANG GU, ROXANE COLLINS, DANIEL D. HOLSWORTH, GREGORY S. WALKER, AND RICHARD L. VOORMAN	2044	Rofecoxib Is a Potent, Metabolism-Dependent Inhibitor of CYP1A2: Implications for in Vitro Prediction of Drug Interactions. MARIO J. KARJALAINEN, PERTTI J. NEUVONEN, AND JANNE T. BACKMAN	2091
Functional Analysis of Mouse and Monkey Multidrug Resistance-Associated Protein 2 (Mrp2). MIZUKI NINOMIYA, KOUSEI ITO, REMI HIRAMATSU, AND TOSHIHARU HORIE	2056	Epirubicin Glucuronidation and UGT2B7 Developmental Expression. MATTHEW J. ZAYA, RONALD N. HINES, AND JEFFREY C. STEVENS	2097
Pharmacokinetics of Berberine and Its Main Metabolites in Conventional and Pseudo Germ-Free Rats Determined by Liquid Chromatography/Ion Trap Mass Spectrometry. FENG ZUO, NORIO NAKAMURA, TERUAKI AKAO, AND MASAO HATTORI	2064	Structure-Activity Relationship and Elucidation of the Determinant Factor(s) Responsible for the Mechanism-Based Inactivation of Cytochrome P450 2B6 by Substituted Phenyl Diaziridines. YOSHIMASA KOBAYASHI, CHITRA SRIDAR, UTE M. KENT, SATISH G. PUPPALI, JOHN M. RIMOLDI, HAOMING ZHANG, LUCY WASKELL, AND PAUL F. HOLLENBERG	2102
The Role of P-glycoprotein in the Bioactivation of Raloxifene. JAE H. CHANG, CHRISTOPHER J. KOCHANSKY, AND MAGANG SHOU	2073	Peracetylation as a Means of Enhancing in Vitro Bioactivity and Bioavailability of Epigallocatechin-3-Gallate. JOSHUA D. LAMBERT, SHENGMING SANG, JUNGIL HONG, SEOK-JOO KWON, MAO-JUNG LEE, CHI-TANG HO, AND CHUNG S. YANG	2111
Drug-Metabolizing Enzyme Inhibition by Ketoconazole Does Not Reduce Interindividual Variability of CYP3A Activity as Measured by Oral Midazolam. MAYLEE CHEN, ANNE N. NAFZIGER, AND JOSEPH S. BERTINO, JR.	2079		
Comparison of Coumarin-Induced Toxicity between Sandwich-Cultured Primary Rat Hepatocytes and Rats in Vivo: A Toxicogenomics Approach.			
		ERRATUM	
		Correction to "Neurotoxic Pyridinium Metabolites of Haloperidol Are Substrates of Human Organic Cation Transporters". by H.-J. KANG, S.-S. LEE, C.-H. LEE, J.-C. SHIM, H. J. SHIN, K.-H. LIU, M.-A. YOO, AND J.-G. SHIN	2117

[S] Supplemental material is available online at <http://dmd.aspetjournals.org>.

About the cover: Molecular model of human FMO3. See the article by Borbás et al. on page 1995 of this issue.